GlaxoSmithKline Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Bhushan Akshikar
Algemeen directeur
₹66.9m
Totale compensatie
Percentage CEO-salaris | 21.7% |
Dienstverband CEO | 1.9yrs |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | 2.1yrs |
Gemiddelde ambtstermijn bestuur | 6.6yrs |
Recente managementupdates
Recent updates
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 30 2024 | n/a | n/a | ₹7b |
Jun 30 2024 | n/a | n/a | ₹6b |
Mar 31 2024 | ₹67m | ₹15m | ₹6b |
Dec 31 2023 | n/a | n/a | ₹5b |
Sep 30 2023 | n/a | n/a | ₹6b |
Jun 30 2023 | n/a | n/a | ₹6b |
Mar 31 2023 | ₹34m | ₹4m | ₹6b |
Compensatie versus markt: De totale vergoeding ($USD 792.12K ) Bhushan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 779.51K ).
Compensatie versus inkomsten: De vergoeding van Bhushan is het afgelopen jaar met meer dan 20% gestegen.
CEO
Bhushan Akshikar
1.9yrs
Tenure
₹66,885,000
Compensatie
Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
MD & Executive Director | 1.9yrs | ₹66.89m | geen gegevens | |
Whole-Time Director & CFO | 2.6yrs | ₹68.92m | geen gegevens | |
Executive Vice President of Human Resources | 3.9yrs | ₹37.40m | geen gegevens | |
Vice President of Technology | less than a year | geen gegevens | geen gegevens | |
VP of Administration & Real Estate and Company Secretary | no data | ₹11.57m | geen gegevens | |
Executive Vice President of Legal | 2.8yrs | geen gegevens | geen gegevens | |
Vice President of Ethics & Compliance | 1.8yrs | geen gegevens | geen gegevens | |
Executive Vice President of Communications & Government Affairs | 7.6yrs | geen gegevens | geen gegevens | |
Executive Vice-President of Regulatory Affairs | no data | geen gegevens | geen gegevens | |
Executive Vice-President of Adult Vaccines | 2.3yrs | geen gegevens | geen gegevens | |
Executive Vice President of General Medicines | 1.9yrs | geen gegevens | geen gegevens | |
Commercial Head - Paediatric Vaccines | 1.8yrs | geen gegevens | geen gegevens |
2.1yrs
Gemiddelde duur
Ervaren management: Het managementteam van GLAXO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
MD & Executive Director | no data | ₹66.89m | geen gegevens | |
Whole-Time Director & CFO | 2.6yrs | ₹68.92m | geen gegevens | |
Non-Executive Chairperson | 5.6yrs | ₹3.25m | geen gegevens | |
Independent Director | 2.5yrs | ₹2.65m | geen gegevens | |
Non-Executive Independent Director | 15.3yrs | ₹2.70m | geen gegevens | |
Non Executive Director | 7.6yrs | geen gegevens | geen gegevens | |
Non-Executive Independent Director | 14.1yrs | ₹2.70m | geen gegevens | |
Non-Executive Independent Director | 13yrs | ₹2.45m | geen gegevens | |
Non-Executive & Independent Director | 4.5yrs | ₹2.45m | geen gegevens |
6.6yrs
Gemiddelde duur
68.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GLAXO wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.6 jaar).